Mina H Hanna1, David J Askenazi, David T Selewski. 1. aDivision of Neonatology, Department of Pediatrics, University of Kentucky, Lexington, Kentucky bDivision of Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama cDivision of Nephrology, Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality in critically ill neonates. Nephrotoxic medication exposure is common in neonates. Nephrotoxicity represents the most potentially avoidable cause of AKI in this population. RECENT FINDINGS: Recent studies in critically ill children revealed the importance of recognizing AKI and potentially modifiable risk factors for the development of AKI such as nephrotoxic medication exposures. Data from critically ill children who have AKI suggest that survivors are at risk for the development of chronic kidney disease. Premature infants are born with incomplete nephrogenesis and are at risk for chronic kidney disease. The use of nephrotoxic medications in the neonatal intensive care unit is very common; yet the effects of medication nephrotoxicity on the short and long-term outcomes remains highly understudied. SUMMARY: The neonatal kidney is predisposed to nephrotoxic AKI. Our ability to improve outcomes for this vulnerable group depends on a heightened awareness of this issue. It is important for clinicians to develop methods to minimize and prevent nephrotoxic AKI in neonates through a multidisciplinary approach aiming at earlier recognition and close monitoring of nephrotoxin-induced AKI.
PURPOSE OF REVIEW: Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality in critically ill neonates. Nephrotoxic medication exposure is common in neonates. Nephrotoxicity represents the most potentially avoidable cause of AKI in this population. RECENT FINDINGS: Recent studies in critically ill children revealed the importance of recognizing AKI and potentially modifiable risk factors for the development of AKI such as nephrotoxic medication exposures. Data from critically ill children who have AKI suggest that survivors are at risk for the development of chronic kidney disease. Premature infants are born with incomplete nephrogenesis and are at risk for chronic kidney disease. The use of nephrotoxic medications in the neonatal intensive care unit is very common; yet the effects of medication nephrotoxicity on the short and long-term outcomes remains highly understudied. SUMMARY: The neonatal kidney is predisposed to nephrotoxic AKI. Our ability to improve outcomes for this vulnerable group depends on a heightened awareness of this issue. It is important for clinicians to develop methods to minimize and prevent nephrotoxic AKI in neonates through a multidisciplinary approach aiming at earlier recognition and close monitoring of nephrotoxin-induced AKI.
Authors: D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L Corey; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S Weller; S J Soong; J Kiell; F D Lakeman; R J Whitley Journal: Pediatrics Date: 2001-08 Impact factor: 7.124
Authors: Matthew M Laughon; Debbie Avant; Nidhi Tripathi; Christoph P Hornik; Michael Cohen-Wolkowiez; Reese H Clark; P Brian Smith; William Rodriguez Journal: JAMA Pediatr Date: 2014-02 Impact factor: 16.193
Authors: João F P Oliveira; Carolina A Silva; Camila D Barbieri; Giselle M Oliveira; Dirce M T Zanetta; Emmanuel A Burdmann Journal: Antimicrob Agents Chemother Date: 2009-04-13 Impact factor: 5.191
Authors: Stuart L Goldstein; Eric Kirkendall; Hovi Nguyen; Joshua K Schaffzin; John Bucuvalas; Tracey Bracke; Michael Seid; Marshall Ashby; Natalie Foertmeyer; Lori Brunner; Anne Lesko; Cynthia Barclay; Carole Lannon; Stephen Muething Journal: Pediatrics Date: 2013-08-12 Impact factor: 7.124
Authors: J E Constance; D Reith; R M Ward; A Balch; C Stockmann; E K Korgenski; E A Thorell; C M T Sherwin Journal: J Perinatol Date: 2017-06-08 Impact factor: 2.521
Authors: Hibo H Abdi; Carl H Backes; Molly K Ball; Maria M Talavera-Barber; Mark A Klebanoff; Sudarshan R Jadcherla; Tahagod H Mohamed; Jonathan L Slaughter Journal: J Perinatol Date: 2021-03-04 Impact factor: 2.521
Authors: Valerie A Luyckx; Norberto Perico; Marco Somaschini; Dario Manfellotto; Herbert Valensise; Irene Cetin; Umberto Simeoni; Karel Allegaert; Bjorn Egil Vikse; Eric A Steegers; Dwomoa Adu; Giovanni Montini; Giuseppe Remuzzi; Barry M Brenner Journal: Lancet Date: 2017-03-09 Impact factor: 79.321
Authors: Mackenzie J Dodge; Katelyn M MacNeil; Tanner M Tessier; Jason B Weinberg; Joe S Mymryk Journal: Antiviral Res Date: 2021-02-10 Impact factor: 5.970